Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 309 entries
Sorted by: Best Match Show Resources per page
Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis.

Translational oncology

Chen R, Peng PC, Wen B, Li FY, Xie S, Chen G, Lu J, Peng Z, Tang SB, Liang YM, Deng X.
PMID: 26947879
Transl Oncol. 2016 Feb;9(1):32-40. doi: 10.1016/j.tranon.2015.11.010.

This systematic review and meta-analysis evaluated anti-programmed cell death (PD)-1 immunotherapy (nivolumab or pembrolizumab) for overall efficacy, safety, and effective dose relative to standard chemotherapy or other conventional drugs in the treatment of malignant tumors. We searched the following...

Cite
Chen R, Peng PC, Wen B, et al. Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis. Transl Oncol. 2016;9(1):32-40doi: 10.1016/j.tranon.2015.11.010.
Chen, R., Peng, P. C., Wen, B., Li, F. Y., Xie, S., Chen, G., Lu, J., Peng, Z., Tang, S. B., Liang, Y. M., & Deng, X. (2016). Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis. Translational oncology, 9(1), 32-40. https://doi.org/10.1016/j.tranon.2015.11.010
Chen, Ran, et al. "Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis." Translational oncology vol. 9,1 (2016): 32-40. doi: https://doi.org/10.1016/j.tranon.2015.11.010
Chen R, Peng PC, Wen B, Li FY, Xie S, Chen G, Lu J, Peng Z, Tang SB, Liang YM, Deng X. Anti-Programmed Cell Death (PD)-1 Immunotherapy for Malignant Tumor: A Systematic Review and Meta-Analysis. Transl Oncol. 2016 Feb;9(1):32-40. doi: 10.1016/j.tranon.2015.11.010. PMID: 26947879; PMCID: PMC4800062.
Copy Download .nbib Format: NLM
Bleomycin-induced flagellate dermatitis.

Revista brasileira de hematologia e hemoterapia

Mota GD, Penna AM, Soares RC, Baiocchi OC.
PMID: 25031171
Rev Bras Hematol Hemoter. 2014 Jul-Aug;36(4):297-9. doi: 10.1016/j.bjhh.2014.03.001. Epub 2014 Apr 03.

A 29-year-old woman with stage IVB Hodgkin's lymphoma was treated with doxorubicin, bleomycin, vinblastine, and dacarbazine. Two weeks after the first cycle was completed, she developed pruritic, linear erythematous lesions in a flagellate-like pattern on the trunk, neck and...

Cite
Mota GD, Penna AM, Soares RC, et al. Bleomycin-induced flagellate dermatitis. Rev Bras Hematol Hemoter. 2014;36(4):297-9doi: 10.1016/j.bjhh.2014.03.001.
Mota, G. D., Penna, A. M., Soares, R. C., & Baiocchi, O. C. (2014). Bleomycin-induced flagellate dermatitis. Revista brasileira de hematologia e hemoterapia, 36(4), 297-9. https://doi.org/10.1016/j.bjhh.2014.03.001
Mota, Guilherme Devidé, et al. "Bleomycin-induced flagellate dermatitis." Revista brasileira de hematologia e hemoterapia vol. 36,4 (2014): 297-9. doi: https://doi.org/10.1016/j.bjhh.2014.03.001
Mota GD, Penna AM, Soares RC, Baiocchi OC. Bleomycin-induced flagellate dermatitis. Rev Bras Hematol Hemoter. 2014 Jul-Aug;36(4):297-9. doi: 10.1016/j.bjhh.2014.03.001. Epub 2014 Apr 03. PMID: 25031171; PMCID: PMC4207924.
Copy Download .nbib Format: NLM
Unusual primary osseous Hodgkin's lymphoma: A case report.

Oncology letters

Luo W, Zhang F, Sun J, He H.
PMID: 25621037
Oncol Lett. 2015 Feb;9(2):677-680. doi: 10.3892/ol.2014.2724. Epub 2014 Nov 20.

Hodgkin's lymphoma (HL) is one of the few adult malignancies that most frequently presents with a progressive, painless enlargement of the peripheral lymph nodes. A primary osseous presentation of HL, without lymph node involvement, is extremely rare. The present...

Cite
Luo W, Zhang F, Sun J, et al. Unusual primary osseous Hodgkin's lymphoma: A case report. Oncol Lett. 2014;9(2):677-680doi: 10.3892/ol.2014.2724.
Luo, W., Zhang, F., Sun, J., & He, H. (2015). Unusual primary osseous Hodgkin's lymphoma: A case report. Oncology letters, 9(2), 677-680. https://doi.org/10.3892/ol.2014.2724
Luo, Wei, et al. "Unusual primary osseous Hodgkin's lymphoma: A case report." Oncology letters vol. 9,2 (2015): 677-680. doi: https://doi.org/10.3892/ol.2014.2724
Luo W, Zhang F, Sun J, He H. Unusual primary osseous Hodgkin's lymphoma: A case report. Oncol Lett. 2015 Feb;9(2):677-680. doi: 10.3892/ol.2014.2724. Epub 2014 Nov 20. PMID: 25621037; PMCID: PMC4301495.
Copy Download .nbib Format: NLM
Brain metabolic changes in Hodgkin disease patients following diagnosis and during the disease course: An .

Oncology letters

Chiaravalloti A, Pagani M, Cantonetti M, DI Pietro B, Tavolozza M, Travascio L, DI Biagio D, Danieli R, Schillaci O.
PMID: 25621038
Oncol Lett. 2015 Feb;9(2):685-690. doi: 10.3892/ol.2014.2765. Epub 2014 Dec 03.

The aim of the present study was to investigate brain glucose metabolism in patients with Hodgkin disease (HD) after diagnosis and during chemotherapy treatment. Following the administration of first-line doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy, 74 HD patients...

Cite
Chiaravalloti A, Pagani M, Cantonetti M, et al. Brain metabolic changes in Hodgkin disease patients following diagnosis and during the disease course: An . Oncol Lett. 2014;9(2):685-690doi: 10.3892/ol.2014.2765.
Chiaravalloti, A., Pagani, M., Cantonetti, M., DI Pietro, B., Tavolozza, M., Travascio, L., DI Biagio, D., Danieli, R., & Schillaci, O. (2015). Brain metabolic changes in Hodgkin disease patients following diagnosis and during the disease course: An . Oncology letters, 9(2), 685-690. https://doi.org/10.3892/ol.2014.2765
Chiaravalloti, Agostino, et al. "Brain metabolic changes in Hodgkin disease patients following diagnosis and during the disease course: An ." Oncology letters vol. 9,2 (2015): 685-690. doi: https://doi.org/10.3892/ol.2014.2765
Chiaravalloti A, Pagani M, Cantonetti M, DI Pietro B, Tavolozza M, Travascio L, DI Biagio D, Danieli R, Schillaci O. Brain metabolic changes in Hodgkin disease patients following diagnosis and during the disease course: An . Oncol Lett. 2015 Feb;9(2):685-690. doi: 10.3892/ol.2014.2765. Epub 2014 Dec 03. PMID: 25621038; PMCID: PMC4301514.
Copy Download .nbib Format: NLM
The benefit of consolidation radiotherapy to initial disease bulk in patients with advanced Hodgkin's disease who achieved complete remission after standard chemotherapy.

Journal of blood medicine

Bayoumi Y, Al-Homaidi A, Zaidi S, Tailor I, Motiabi I, Alshehri N, Al-Ghazali A, Almudaibigh S.
PMID: 25848329
J Blood Med. 2015 Mar 20;6:87-92. doi: 10.2147/JBM.S69267. eCollection 2015.

BACKGROUND/PURPOSE: The aim of this study was to evaluate the role of consolidation radiotherapy (RT) in advanced-stage Hodgkin's disease (HD) with initial bulky sites after radiological complete remission (CR) or partial response (PR) with positron emission tomography-negative (metabolic CR)...

Cite
Bayoumi Y, Al-Homaidi A, Zaidi S, et al. The benefit of consolidation radiotherapy to initial disease bulk in patients with advanced Hodgkin's disease who achieved complete remission after standard chemotherapy. J Blood Med. 2015;6:87-92doi: 10.2147/JBM.S69267.
Bayoumi, Y., Al-Homaidi, A., Zaidi, S., Tailor, I., Motiabi, I., Alshehri, N., Al-Ghazali, A., & Almudaibigh, S. (2015). The benefit of consolidation radiotherapy to initial disease bulk in patients with advanced Hodgkin's disease who achieved complete remission after standard chemotherapy. Journal of blood medicine, 687-92. https://doi.org/10.2147/JBM.S69267
Bayoumi, Yasser, et al. "The benefit of consolidation radiotherapy to initial disease bulk in patients with advanced Hodgkin's disease who achieved complete remission after standard chemotherapy." Journal of blood medicine vol. 6 (2015): 87-92. doi: https://doi.org/10.2147/JBM.S69267
Bayoumi Y, Al-Homaidi A, Zaidi S, Tailor I, Motiabi I, Alshehri N, Al-Ghazali A, Almudaibigh S. The benefit of consolidation radiotherapy to initial disease bulk in patients with advanced Hodgkin's disease who achieved complete remission after standard chemotherapy. J Blood Med. 2015 Mar 20;6:87-92. doi: 10.2147/JBM.S69267. eCollection 2015. PMID: 25848329; PMCID: PMC4374789.
Copy Download .nbib Format: NLM
Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma.

Therapeutic advances in hematology

Sethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N.
PMID: 28042455
Ther Adv Hematol. 2017 Jan;8(1):13-20. doi: 10.1177/2040620716676256. Epub 2016 Oct 30.

BACKGROUND: Nodular sclerosis Hodgkin lymphoma (NS-HL) is the most common subtype of HL and usually has a good prognosis. A variant of NS, the syncytial variant (SV) has well-established histopathologic features but little is known about its clinical behavior....

Cite
Sethi T, Nguyen V, Li S, et al. Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma. Ther Adv Hematol. 2016;8(1):13-20doi: 10.1177/2040620716676256.
Sethi, T., Nguyen, V., Li, S., Morgan, D., Greer, J., & Reddy, N. (2017). Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma. Therapeutic advances in hematology, 8(1), 13-20. https://doi.org/10.1177/2040620716676256
Sethi, Tarsheen, et al. "Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma." Therapeutic advances in hematology vol. 8,1 (2017): 13-20. doi: https://doi.org/10.1177/2040620716676256
Sethi T, Nguyen V, Li S, Morgan D, Greer J, Reddy N. Differences in outcome of patients with syncytial variant Hodgkin lymphoma compared with typical nodular sclerosis Hodgkin lymphoma. Ther Adv Hematol. 2017 Jan;8(1):13-20. doi: 10.1177/2040620716676256. Epub 2016 Oct 30. PMID: 28042455; PMCID: PMC5167078.
Copy Download .nbib Format: NLM
Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer.

Journal of personalized medicine

Kelleher FC, Solomon B, McArthur GA.
PMID: 25562798
J Pers Med. 2012 Apr 10;2(2):35-49. doi: 10.3390/jpm2020035.

The incorporation of individualized molecular therapeutics into routine clinical practice for both non-small cell lung cancer (NSCLC) and melanoma are amongst the most significant advances of the last decades in medical oncology. In NSCLC activating somatic mutations in exons...

Cite
Kelleher FC, Solomon B, McArthur GA. Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer. J Pers Med. 2012;2(2):35-49doi: 10.3390/jpm2020035.
Kelleher, F. C., Solomon, B., & McArthur, G. A. (2012). Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer. Journal of personalized medicine, 2(2), 35-49. https://doi.org/10.3390/jpm2020035
Kelleher, Fergal C, et al. "Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer." Journal of personalized medicine vol. 2,2 (2012): 35-49. doi: https://doi.org/10.3390/jpm2020035
Kelleher FC, Solomon B, McArthur GA. Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer. J Pers Med. 2012 Apr 10;2(2):35-49. doi: 10.3390/jpm2020035. PMID: 25562798; PMCID: PMC4251364.
Copy Download .nbib Format: NLM
CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function.

Biomarker research

Thakar K, Novero A, Das A, Lisinschi A, Mehta B, Ahmed T, Liu D.
PMID: 24991411
Biomark Res. 2014 Jun 23;2:12. doi: 10.1186/2050-7771-2-12. eCollection 2014.

ABVD regimen (doxorubicin, bleomycin, vinblastine and dacarbazine) remains the most commonly used front-line therapy for Hodgkin lymphoma. However, atypical and extranodal presentations present challenges to initial therapy, especially in the presence of renal and liver failure. We hereby present...

Cite
Thakar K, Novero A, Das A, et al. CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function. Biomark Res. 2014;2:12doi: 10.1186/2050-7771-2-12.
Thakar, K., Novero, A., Das, A., Lisinschi, A., Mehta, B., Ahmed, T., & Liu, D. (2014). CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function. Biomarker research, 212. https://doi.org/10.1186/2050-7771-2-12
Thakar, Keyur, et al. "CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function." Biomarker research vol. 2 (2014): 12. doi: https://doi.org/10.1186/2050-7771-2-12
Thakar K, Novero A, Das A, Lisinschi A, Mehta B, Ahmed T, Liu D. CEPP regimen (cyclophosphamide, etoposide, procarbazine and prednisone) as initial treatment for Hodgkin lymphoma patients presenting with severe abnormal liver function. Biomark Res. 2014 Jun 23;2:12. doi: 10.1186/2050-7771-2-12. eCollection 2014. PMID: 24991411; PMCID: PMC4078319.
Copy Download .nbib Format: NLM
Pattern of CD4 T-lymphocyte Values in Cancer Patients on Cytotoxic Therapy.

Annals of medical and health sciences research

Madu A, Ocheni S, Ibegbulam O, Aguwa E, Madu K.
PMID: 24379998
Ann Med Health Sci Res. 2013 Oct;3(4):498-503. doi: 10.4103/2141-9248.122054.

BACKGROUND: Assessment of patients prior to cytotoxic chemotherapy usually includes absolute neutrophils count. Other cellular markers of susceptibility to infection as well as immunocompetence include the T Helper lymphocyte count. In cancer patients, decrease in these lymphocytes has been...

Cite
Madu A, Ocheni S, Ibegbulam O, et al. Pattern of CD4 T-lymphocyte Values in Cancer Patients on Cytotoxic Therapy. Ann Med Health Sci Res. 2013;3(4):498-503doi: 10.4103/2141-9248.122054.
Madu, A., Ocheni, S., Ibegbulam, O., Aguwa, E., & Madu, K. (2013). Pattern of CD4 T-lymphocyte Values in Cancer Patients on Cytotoxic Therapy. Annals of medical and health sciences research, 3(4), 498-503. https://doi.org/10.4103/2141-9248.122054
Madu, Aj, et al. "Pattern of CD4 T-lymphocyte Values in Cancer Patients on Cytotoxic Therapy." Annals of medical and health sciences research vol. 3,4 (2013): 498-503. doi: https://doi.org/10.4103/2141-9248.122054
Madu A, Ocheni S, Ibegbulam O, Aguwa E, Madu K. Pattern of CD4 T-lymphocyte Values in Cancer Patients on Cytotoxic Therapy. Ann Med Health Sci Res. 2013 Oct;3(4):498-503. doi: 10.4103/2141-9248.122054. PMID: 24379998; PMCID: PMC3868113.
Copy Download .nbib Format: NLM
Coexistence of Hodgkin's Lymphoma and Castleman's Disease: A Case Report with Successful Response to Chemotherapy and Radiotherapy.

Case reports in oncological medicine

Mohtaram A, Afif M, Sghiri T, Rami A, Latib R, Kettani F, Ben Ameur El Youbi M, Boutayeb S, Kebdani T, Benjaafar N, Aaribi I, Errihani H.
PMID: 24381772
Case Rep Oncol Med. 2013;2013:487205. doi: 10.1155/2013/487205. Epub 2013 Dec 05.

Background. Castleman's disease is a rare clinicopathological entity of unknown origin. Coexistence of Hodgkin's lymphoma and Castleman's disease is rare. We report a case of Hodgkin's disease of cervical lymph nodes in a patient previously diagnosed with Castleman's disease....

Cite
Mohtaram A, Afif M, Sghiri T, et al. Coexistence of Hodgkin's Lymphoma and Castleman's Disease: A Case Report with Successful Response to Chemotherapy and Radiotherapy. Case Rep Oncol Med. 2013;2013:487205doi: 10.1155/2013/487205.
Mohtaram, A., Afif, M., Sghiri, T., Rami, A., Latib, R., Kettani, F., Ben Ameur El Youbi, M., Boutayeb, S., Kebdani, T., Benjaafar, N., Aaribi, I., & Errihani, H. (2013). Coexistence of Hodgkin's Lymphoma and Castleman's Disease: A Case Report with Successful Response to Chemotherapy and Radiotherapy. Case reports in oncological medicine, 2013487205. https://doi.org/10.1155/2013/487205
Mohtaram, Amina, et al. "Coexistence of Hodgkin's Lymphoma and Castleman's Disease: A Case Report with Successful Response to Chemotherapy and Radiotherapy." Case reports in oncological medicine vol. 2013 (2013): 487205. doi: https://doi.org/10.1155/2013/487205
Mohtaram A, Afif M, Sghiri T, Rami A, Latib R, Kettani F, Ben Ameur El Youbi M, Boutayeb S, Kebdani T, Benjaafar N, Aaribi I, Errihani H. Coexistence of Hodgkin's Lymphoma and Castleman's Disease: A Case Report with Successful Response to Chemotherapy and Radiotherapy. Case Rep Oncol Med. 2013;2013:487205. doi: 10.1155/2013/487205. Epub 2013 Dec 05. PMID: 24381772; PMCID: PMC3870129.
Copy Download .nbib Format: NLM
Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas.

Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology

Noujaim J, Alam S, Thway K, Jones RL.
PMID: 27688604
Indian J Med Paediatr Oncol. 2016 Jul-Sep;37(3):125-30. doi: 10.4103/0971-5851.190359.

Despite recent advances in the field, treatment options for metastatic soft tissue sarcoma patients are limited. Eribulin, an antimitotic derived from the natural marine sponge product halichondrin B, is currently approved for the treatment of metastatic breast cancer. Following...

Cite
Noujaim J, Alam S, Thway K, et al. Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas. Indian J Med Paediatr Oncol. 2016;37(3):125-30doi: 10.4103/0971-5851.190359.
Noujaim, J., Alam, S., Thway, K., & Jones, R. L. (2016). Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas. Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology, 37(3), 125-30. https://doi.org/10.4103/0971-5851.190359
Noujaim, Jonathan, et al. "Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas." Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology vol. 37,3 (2016): 125-30. doi: https://doi.org/10.4103/0971-5851.190359
Noujaim J, Alam S, Thway K, Jones RL. Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas. Indian J Med Paediatr Oncol. 2016 Jul-Sep;37(3):125-30. doi: 10.4103/0971-5851.190359. PMID: 27688604; PMCID: PMC5027783.
Copy Download .nbib Format: NLM
Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease.

Seminars in radiation oncology

Cosset JM, Fermé C, Noordijk EM, Dubray BM, Thirion P, Henry-Amar M.
PMID: 10717177
Semin Radiat Oncol. 1996 Jul;6(3):185-195. doi: 10.1053/SRAO00600185.

Recommendations for the treatment of "poor prognosis" stages I and II Hodgkin's disease (HD) depend on the extent of staging. For centers that favor exploratory laparotomy and splenectomy, the standard treatment after negative surgical staging remains subtotal lymphoid irradiation....

Cite
Cosset JM, Fermé C, Noordijk EM, et al. Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease. Semin Radiat Oncol. 1996;6(3):185-195doi: 10.1053/SRAO00600185.
Cosset, J. M., Fermé, C., Noordijk, E. M., Dubray, B. M., Thirion, P., & Henry-Amar, M. (1996). Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease. Seminars in radiation oncology, 6(3), 185-195. https://doi.org/10.1053/SRAO00600185
Cosset, et al. "Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease." Seminars in radiation oncology vol. 6,3 (1996): 185-195. doi: https://doi.org/10.1053/SRAO00600185
Cosset JM, Fermé C, Noordijk EM, Dubray BM, Thirion P, Henry-Amar M. Combined Modality Treatment for Poor Prognosis Stages I and II Hodgkin's Disease. Semin Radiat Oncol. 1996 Jul;6(3):185-195. doi: 10.1053/SRAO00600185. PMID: 10717177.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 309 entries